If I were to venture a guess, I would say positive Phase 3 Amigal results. I don't have idea what the stock may do on that news. I have no position in the stock and I don't think positive Amigal results are enough to sway me. jq1234, turtle (maybe others?) and I have had discussion about this in the past if you want to search this board (I don't have search but you do :-)).
While the disease focus is similar to BMRN I wouldn't say they are anywhere near being an up and coming BMRN. If their chaperon would work in Pompe it'd be more interesting to me. Perhaps in Alzheimer's or Parkinsons they'll get lucky but that is a speculation I don't want to pay for at this stage.
Glaxo went to a meeting with FOLD in May reviewed all the trial data FOLD had to date and Glaxo left the meeting and upped their stake in FOLD paying well over $6 per share.011 which is their big trial, that Data is going to be unblinded sometime in next 30 days give or take a few..All 66 patients in the trial signed back up for another 6 months and Folds drug is all they have taken for the past 6 months....the drug appears to be working on the patients.Fabry is a very painful disease, there's ust no way these people could have made it this long just taking FOLD's drug if it was not effective imho.
Market Data 
Markets 
AI
